🔎 Trials Near Me

Utama › Kanser Darah › Texas › Dallas

Kajian klinikal Kanser Darah di Dallas, TX

12 kajian untuk Kanser Darah sedang mencari peserta di lokasi dalam dan sekitar Dallas (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Mengambil pesertaFasa 3
  • Texas Oncology-Baylor Sammons Cancer Center ( Site 0062), Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03486873

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Mengambil pesertaFasa 2
  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04728893

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Mengambil pesertaFasa 1
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mengambil pesertaFasa 1/2
  • Baylor Scott & White Health, Dallas
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Mengambil pesertaFasa 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Mengambil pesertaFasa 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Mengambil pesertaKajian pemerhatian
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Mengambil pesertaFasa 1
  • UT Southwestern Medical Center, Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jun 2026 · NCT02074839

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Mengambil pesertaFasa 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Umur 2 hingga 18 · Semua jantina · Dikemas kini 5 Mei 2026 · NCT05711667

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Mengambil peserta
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Umur 6 hingga 29 · Semua jantina · Dikemas kini 4 Mei 2026 · NCT04678427

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Mengambil pesertaFasa 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Mengambil pesertaFasa 1
  • University of Texas, Southwestern, Dallas
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Kajian Kanser Darah di bandar lain

Kajian lain di Dallas

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.